Apellis PharmaceuticalsAPLS
Market Cap: $5B
About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Employees: 702
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
359% more call options, than puts
Call options by funds: $230M | Put options by funds: $50M
86% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 66
0.77% more ownership
Funds ownership: 94.27% [Q1] → 95.04% (+0.77%) [Q2]
13% less funds holding
Funds holding: 297 [Q1] → 259 (-38) [Q2]
34% less capital invested
Capital invested by funds: $6.68B [Q1] → $4.42B (-$2.26B) [Q2]
38% less funds holding in top 10
Funds holding in top 10: 8 [Q1] → 5 (-3) [Q2]
54% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 71
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
14 analyst ratings
JP Morgan Anupam Rama 55% 1-year accuracy 23 / 42 met price target | 56%upside $64 | Overweight Maintained | 13 Aug 2024 |
UBS Eliana Merle 58% 1-year accuracy 7 / 12 met price target | 102%upside $83 | Buy Maintained | 9 Aug 2024 |
Wedbush Laura Chico 44% 1-year accuracy 33 / 75 met price target | 0%downside $41 | Neutral Maintained | 9 Aug 2024 |
Goldman Sachs Salveen Richter 50% 1-year accuracy 10 / 20 met price target | 80%upside $74 | Buy Maintained | 9 Aug 2024 |
Baird Colleen Kusy 35% 1-year accuracy 6 / 17 met price target | 134%upside $96 | Outperform Maintained | 9 Aug 2024 |
Financial journalist opinion
Based on 4 articles about APLS published over the past 30 days